Global Genome Editing Market Is Expected to Reach USD 17.36 Billion by 2028 : Fior Markets Genome Editing Market by Technology(ZFN, TALENs/MegaTALs, CRISPR/Cas9, Others), Delivery Method (In-Vivo, Ex-Vivo), Application (Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering, Other Applications), End-Use (Contract Research Organizations, Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies), Service (In-house, Contract), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2021 to 2028
February 17, 2021 19:00 ET | Source: Fior Markets Fior Markets Pune, INDIA
Newark, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) As per the report published by Fior Markets, the
global genome editing market is expected to grow from USD 5.37 billion in 2020 to USD 17.36 billion by 2028, at a CAGR of 15.8% during the forecast period 2021-2028.
Global Genome Editing Market Is Expected to Reach USD 17 36 Billion by 2028 : Fior Markets benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
4basebio UK Societas - Admission to Trading on AIM and First Day of Dealings
PR Newswire
Admission to Trading on AIM and First Day of Dealings
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, is pleased to announce the admission of its ordinary shares to trading on the AIM market of the London Stock Exchange. Dealings will commence at 8.00 a.m. today, Wednesday 17 February 2021, under the ticker 4BB (ISIN GB00BLD8ZL39).
Upon Admission, the Company will have 12,317,473 ordinary shares in issue and a market capitalisation of approximately £14.5 million.
4basebio UK Societas COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: 4basebio UK Societas ( 4bb or the Company ) is a specialist life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its main country of operation is the UK. It is the intention of the Company to become a market leader in the manufacture and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process with a view to manufacturing Good Manufacturing Practice ( GMP ) grade DNA, suitable for use in gene t